Replication competent viruses hold promise for treatment of advanced cancers resistant to available therapeutic modalities. Although preliminary clinical results have substantiated their efficacy, preclinical development of these novel approaches is limited by assay substrates. The evaluation of candidate agents could be confounded by differences between primary tumor cells and tumor cell lines, as discordance in the levels of surface receptors relevant for viral entry has been reported. Since primary tumor cells are difficult to analyze ex vivo for longitudinal observation of virus replication, we developed three-dimensional aggregates or spheroids of unpassaged and purified ovarian cancer cells as a means for prolonging primary tumor cell viability and as a threedimensional in vitro model for replicative viral infection. Ovarian cancer cells purified from ascites samples were sustained for 30 days while retaining the infection profile with tropism modified and unmodified adenoviruses (Ads). Cell line and primary cell spheroids were used to quantitate the replication and oncolytic potency of replicative Ads in preclinical testing for human ovarian cancer trials. Therefore, spheroids provide a method to sustain purified unpassaged primary ovarian cancer cells for extended periods and to allow evaluation of replicative viruses in a three-dimensional model.
C
ancer is the second leading cause of mortality in the US and accounts for over 500,000 deaths annually. Current treatment modalities are especially inadequate for advanced disease. Recently, clinical improvements in the treatment of severe combined immunodeficiency, 1 hemophilia, 2 and atherosclerosis 3 have validated the concept of gene therapy for a therapeutic benefit. Likewise, gene therapy approaches for cancer have also demonstrated promising results. [4] [5] [6] However, the primary conclusion from cancer gene therapy trials is that, although safety has been good, gene transfer to tumor cells remains the key factor limiting clinical efficacy. A powerful approach for improving transduction is using conditionally replicative viral agents, which allow effective penetration into the tumor and local amplification of the therapeutic effect. 4, 7 Among such agents, adenoviruses (Ads) allow high titer production and achieve unparalleled transduction efficacy of dividing and quiescent cells. These qualities are reflected by Ad, now being the most popular agent in cancer trials 8 and the only one to show evidence of efficacy. [4] [5] [6] Ongoing efforts to increase Ad effectiveness include infectivity enhancement and retargeting strategies that increase tumor transduction while minimizing insult to non-neoplastic tissues. Furthermore, clinical trials with Ad have demonstrated the safety of the agent with over 700 cancer patients treated without therapy-related mortality, including nearly 300 treated with conditionally replicative adenoviruses (CRAds). 9 Therefore, CRAds represent a safe and potentially effective tool for cancer gene therapy. The utility of Ads for cancer therapy stems from its transduction characteristics, which are perhaps the best understood of all viral vectors. The rate-limiting step of Ad infection is binding to the primary receptor, coxsackie-adenovirus receptor (CAR). [10] [11] [12] With replicating viral agents, transduction efficacy has been shown to be the main determinant of oncolytic potency. [13] [14] [15] In contrast to many cell lines, however, CAR expression varies greatly and is often lower in various primary tumor cells types 11, 12, [16] [17] [18] [19] [20] [21] including ovarian cancers. [22] [23] [24] [25] Conceivably, the selection process involved in obtaining immortalized cell lines from cancer cells could cause other changes also. Therefore, primary tumor cells might better model in vivo tumor behavior for the analysis of novel agents.
Problems encountered using primary tumor samples include contaminating normal cells and limited viability of primary tumor cells in vitro. To obtain a pure tumor cell population, we have developed a method for purification of ovarian cancer cells from patient ascites. 26 While these cells survive in vitro for only a few days without passaging, 27 many CRAd assays require several weeks for completion. The clonal selection involved in adaptation to replication and growth as a monolayer in vitro can cause genotypic and phenotypic changes, which could contribute to the discordance seen in expression of receptors involved in viral entry. To address this need, we report here the development of ovarian cancer spheroids, which allow extension of purified unpassaged primary tumor cell viability for analysis of replicative viral agents in a three-dimensional system.
Spheroids are three-dimensional clusters of cells and have been utilized to study tumor biology, chemotherapy, and radiation therapy. 28 Gene therapy studies have employed spheroids based on cell lines, 29, 30 and a recent study reports the use of unpurified glioma explants for studying transduction with nonreplicative Ads. 31 Here, we report the first spheroid model for assessing replication competent viruses on purified primary cancer cells. First, we investigated the viability of primary cancer cells in a spheroid system. Then, Ad infectivity patterns were compared in spheroid and monolayer cultures. Next, replication competent Ads expressing a reporter gene were used to assess adenovirus replication kinetics in spheroids. Finally, primary tumor cell spheroids were utilized to evaluate replication of a clinically applicable CRAd in patient samples.
Materials and methods

Cell lines and primary tumor cells
The human ovarian adenocarcinoma cell lines SKO-V3.ip1, Hey, and OV-4 were obtained from Drs Janet Price and Judy Wolf (both of the University of Texas MD Anderson Cancer Center, Houston, TX), and Dr Timothy J Eberlein (Harvard Medical School, Boston, MA), respectively. The 293 cell line was purchased from Microbix (Toronto, Canada). All cell lines were cultured in conditions recommended by their suppliers. Infection media had 2% fetal bovine serum. RPMI-1640 growth medium supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 100 IU/ml penicillin, and 25 mg/ml streptomycin was used for culture of the primary ovarian adenocarcinoma cells that were purified from malignant ascites samples obtained at our institution following informed consent from patients with pathologically confirmed ovarian adenocarcinoma. The previously described purification of the tumor cells 26 was utilized to achieve a 63-96% tumor cell purity. After most erythrocytes were removed with a lysis buffer, the tumor cells were extracted from benign cells using the CC49 monoclonal mouse antibody (Biological Resources Branch of the National Cancer Institute, Rockville, MD), Pan Mouse IgG Dynabeads (Dynal AS, Oslo, Norway) coated with anti-mouse IgG antibodies, and a magnetic particle concentrator (Dynal).
Recombinant Ads
Ad5luc1,
32
Ad5lucRGD,
22
Ad5-Luc3, 33 and Ad5-D24RGD 34 have been previously reported. The Ad5-D24RGD was propagated on A549 cells. The other viruses were propagated on 293 cells, and all were purified on cesium chloride gradients. The viral particle (VP) concentrations determined at 260 nm were 1.28 Â 10 11 , 3.25 Â 10 11 , 1.1 Â 10
12
, and 2.6 Â 10 12 VP/ml for Ad5luc1, Ad5lucRGD, Ad5-Luc3, and Ad5-D24RGD, respectively. To determine the functional titer of the viruses, we performed plaque assays with an overnight infection to allow entry of all functional virions without confounding by receptor density. The Ad5luc1, Ad5lucRGD, Ad5-Luc3, and Ad5-D24RGD viruses had titers of 4.7 Â 10 10 , 2.9 Â 10 10 , 2 Â 10 10 , and 5.2 Â 10 10 plaque-forming units (PFU)/ml, respectively. The E1 region was amplified with PCR to detect the absence of wild-type contamination (Ad5luc1 and Ad5lucRGD), the presence of E1, or the presence of the 24 bp deletion, respectively.
Culture of spheroids
To prepare agar-coated flasks and plates, agar was dissolved in deionized water to reach a 3% concentration and autoclaved. The solution was poured into flasks or multiwell plates and allowed to solidify at room temperature. For culture of spheroids, cells were suspended with growth media into concentrations of 1-10 million cells/ml, added to the agar-coated containers, and subjected to intermittent agitation on a rocking platform.
Immunostaining of tumor primary spheroids
Primary tumor cell spheroids were transferred in Hanks' balanced salt solution 1 and 30 days after purification onto glass slides, air-dried, and fixed with Cell-Fixx (Thermo Shandon, Pittsburgh, PA). Immunohistochemical staining with antibodies specific for B72.3 or EMA (epithelial membrane antigen) (both Ventana Medical Systems, Inc., Tucson, AZ) were performed by using vendor recommended protocols in an ES-automated immunostainer (Ventana). The B72.3 antibody has been shown to have a high sensitivity and specificity for ovarian cancer cells. 26, 35, 36 Infections of spheroids and monolayers
The tumor cell line spheroids composed of SKOV3.ip1, OV-4, or Hey cells were removed from their agar-coated flasks and filtered through a 200 mesh screen with 75 mm pores (Sigma Chemical Co., St Louis, MO) to separate the larger spheroids from the smaller ones and single cells.
A fraction of the spheroids was used to estimate the average number of surface cells within each spheroid by staining with crystal violet (see below). The remaining spheroids were divided into equal aliquots, resuspended in 500 ml of infection media with 0, 1, 10, or 100 PFU/surface cell of Ad5luc1 or Ad5lucRGD, and incubated on a rocking platform for 1 hour before transfer in fresh growth medium into separate agar-coated wells. After 30-hour incubation, Bright-Glo Luciferase Assay Reagent (Promega Corporation, Madison, WI) was used to assay gene transfer. Normalization for variance in cell number between samples was achieved by measuring protein concentration with the Bio-Rad DC protein assay (BioRad Laboratories, Hercules, CA) and surface cell staining (see below). Primary ovarian adenocarcinoma cell spheroids were infected in similar fashion except that no filtration or staining was performed because of their smaller size.
Tumor cell line monolayer infections were performed by seeding 10 5 SKOV3.ip1, OV-4, or Hey cells into each well. After overnight incubation, growth media from each well was replaced by 500 ml of infection media with either 0, 1, 10, or 100 PFU/cell of Ad5luc1 or Ad5lucRGD. After 1-hour incubation on a rocking platform, the virus and infection medium solution was replaced by fresh growth medium. Following a 30-hour incubation, the Luciferase Assay System (Promega Corporation, Madison, WI) was used to quantify gene transfer for the tumor cell lines. Variations in cell number were normalized for by the Bio-Rad DC protein assay (Bio-Rad). Infection of purified primary ovarian adenocarcinoma cell monolayers was performed as described above, except that they were seeded onto Biocoat Cell Environment type I collagencoated 24-well plates (Becton Dickinson Labware, Bedford, MA) instead of standard multiwell plates, and their luciferase expression was quantified by Bright-Glo Luciferase Assay Reagent (Promega Corporation, Madison, WI).
Next, spheroids were infected with replication competent Ad. After mesh filtering and surface cell staining (see below), equal aliquots of Hey spheroids were transferred to 3% agar-coated wells with 2% infection media and 0, 10, 100, or 1000 PFU/surface cell of Ad5-Luc3. After 1-hour incubation on a rocking platform, enough fetal bovine serum was added to achieve a 10% concentration in each well. Beginning 24 hours after the infection and daily thereafter, the supernatant was entirely extracted from each well and replaced with fresh growth media. Supernatant luciferase has been measured to quantify oncolysis. 37 We employed this assay using Bright-Glo Luciferase Assay Reagent until all luminometer readings reached baseline. Mock infection measurements were subtracted from the readings of the viral-infected groups. Primary ovarian adenocarcinoma cell spheroids were infected in similar fashion, but because of their small size, no filtration or staining was performed.
Primary ovarian adenocarcinoma spheroids were infected with Ad5-D24RGD or the nonreplicative control Ad5lucRGD by resuspension in infection medium with 0, 0.2, 2, or 2 PFU/surface cell of either virus in 3% agarcoated wells. At 1 hour after infection, enough fetal bovine serum was added to achieve a 10% concentration in each well. At 24 hours after infection, the spheroids from each well were divided into multiple equal aliquots (one for each daily measurement) and each resuspended in 200 ml of growth medium. One aliquot of spheroids from each viral dose was frozen at À201C each day after infection. DNA was extracted and purified from the cellular fractions of these samples with the QIAamp DNA Mini Kit (Qiagen Inc., Valencia, CA) and from the supernatant fractions with the QIAamp DNA Blood Mini Kit (Qiagen). Quantitative PCR has been employed to analyze adenovirus replication [38] [39] [40] and was performed on these DNA samples with a Roche Lightcycler (Roche Diagnostics Corporation, Indianapolis, IN) as described. 41 The viral DNA copies detected were normalized by quantitative PCR for actin copies, except for the first experiment, which was normalized by cell number. Since zero cannot be displayed on a logarithmic scale, baseline values were set as 1 and sample readings are presented relative to the baseline.
Staining of spheroid surface cells
Since replication incompetent Ad transduction was expected to be limited to the superficial layers of spheroids, 29 we used the ratio of Ad PFU to spheroid surface cells rather than the Ad PFU to total cell ratio for infections. To estimate the proportion of surface cells in each particular spheroid sample, a fraction of each group was mixed with crystal violet and incubated at room temperature for 20-60 minutes. Washings with phosphate-buffered saline removed excess crystal violet, and the spheroids were resuspended in 2.5% (10 Â ) trypsin followed by disruption into individual cells by repeated vortexing with intermittent 371C incubation. The number of stained surface cells and unstained core cells was then determined by microscopic examination.
Results
Spheroids provide a novel method for prolonging the viability of purified unpassaged tumor primary samples Both ovarian cancer cell lines and primary ovarian cancer cells spontaneously aggregated to form spheroids within a day of their resuspension in agar-coated containers. Most tumor cell line spheroids ranged in size from 50 to 1000 mm in diameter, and primary tumor cell spheroids were usually smaller, ranging from 10 to 100 mm in diameter. Microscopic evaluation showed that the purified primary tumor cell spheroids were morphologically similar to the unpurified primary tumor cell clusters in fresh patient ascites (Fig 1a) . Spheroids from four of five patient samples showed reactive staining (brown) with the ovarian adenocarcinoma-specific B72.3 antibody after 1 day of culture (Fig 1b) . The same four samples also showed the same positive staining after 30 days in culture (Fig 1c) . Spheroids from five primary ovarian adenocarcinoma cell samples showed reactivity with another adenocarcinoma-specific antibody, anti-EMA, after 1 day in culture. All five of these samples also stained positively with EMA after 30 days in culture (data not shown). In all positive samples, neither antibody showed significant decrease in staining intensity or cellular distribution after the 30-day spheroid incubations.
Spheroids provide a valid model for assessment of adenovirus infectivity
The validity of the surface cell staining method for estimation of surface cell proportion was substantiated by multiple stainings compared with the following mathematical equations: 1) surface area of sphere ¼ 4pr 2 ; 2) volume of sphere ¼ (4/3) pr 3 ; 3) and area of circle ¼ pr 2 . Measurement of spheroid and individual cell diameters allowed for estimation of spheroid and single cell volumes in addition to exposed surface area of both spheroids and individual surface cells. Based on these calculations, one group of spheroids was mathematically estimated to have 16% surface cells. Actual staining of these spheroids showed that approximately 23% of all cells were surface cells.
Since previous reports have shown that the integrin binding RGD-4C motif in the HI-loop of the serotype 5 Ad fiber allows CAR-independent transduction of ovarian cancer cells, 22 we used Ad5lucRGD and the isogenic Ad5-Luc1 (wild-type fiber) to indirectly assess CAR and integrin expression on spheroids compared to monolayers. Infections of SKOV3.ip1, OV-4, and Hey monolayers with Ad5lucRGD produced one to two orders of magnitude increased gene expression in comparison to Ad5luc1 at doses of 1, 10, and 100 PFU/cell. Similar transduction patterns were seen for the respective spheroid infections (Fig 2a-c) .
In primary cell spheroids derived from Patient A, Ad5lucRGD exhibited 7.4-, 10.0-, and 10.0-fold greater luciferase expression than Ad5luc1 at 1, 10, and 100 PFU/ surface cell, respectively. In monolayers derived from Patient A cells, the respective differences in gene transfer were 15-, 8.3-, and 3.8-fold (Fig 2d) . For Patient B, Ad5LucRGD infections resulted in 8.9-, 19-, and 7.9-fold higher luciferase readings than Ad5luc1 infections in spheroids, while for monolayers these differences were 4.8-, 4.0-, and 2.7-fold, respectively (Fig 2e) . showed measurable supernatant luciferase ranging from 1 Â 10 2 to 1 Â 10 7 relative light units (RLU) 9-14 days after infection (Fig 3a) . Despite complete daily medium changes, all three groups showed an overall increase in supernatant luciferase over the first 2-5 days and peaks in luciferase release on days 2, 3, and 5 with doses of 1000, 100, and 10 PFU/surface cell, respectively. Purified unpassaged primary ovarian cancer cell spheroids infected with Ad5-Luc3 showed measurable luciferase expression ranging from 1 Â 10 2 to 1 Â 10 7 RLU in their supernatants (Fig 3b) . Measurable levels of supernatant luciferase remained up to 17 days after infection.
Spheroids allow use of purified unpassaged primary tumor cells in a three-dimensional model for quantifying replication of a clinically applicable CRAd
Quantitative PCR detection of Ad5-D24RGD in infected primary ovarian adenocarcinoma cell spheroids gave measurable results throughout the duration of all experiments (up to 17 days) at all viral doses used (Fig 4) . Furthermore, the number of gene copies generally increased over the durations of each experiment. The first infection was observed for 5 days during which viral DNA copies increased 2.6 Â 10 5 -, 1.9 Â 10 9 -, and 3.0 Â 10 7 -fold for doses of 0.2, 2, and 20 PFU/surface cell, respectively (Fig 4a) . The longer duration of the second experiment allowed samples with 2 and 20 PFU/ surface cell doses of Ad5-D24RGD to reach peak virus production 9 and 11 days after infection, respectively (Fig  4b) . In comparison to day 1, these samples showed 168-and 708-fold increases in viral copy number, respectively. The two last infections show peaks in viral DNA at 8 and 14 days after infection (Fig 4c) and at days 14 and 15 after infection (Fig 4d) at doses of 2 and 20 PFU/surface cell, respectively. Increases in viral DNA were 2730-and 3600-fold (Fig 4c) and 4630-and 1150-fold (Fig 4d) , respectively. Gene copies of the E1-deleted control virus Ad5lucRGD showed 97.6-, 39.5-, and 149-fold increases in the second, third, and fourth experiments, respectively (Fig 4b-d) . To estimate total virus production by the spheroids, cumulative virus copy number was calculated (Fig 4e-h) . In all cases, the highest cumulative virus copy number was detected with 20 PFU/surface cell of Ad5-D24RGD. When compared to the respective dose of the E1-deleted control virus, Ad5-D24RGD produced 9-, 86-, and 25-fold more virus (Fig 4f-h) .
Discussion
Gene therapy has recently produced clinical breakthroughs in treatment of a heterogeneous group of hereditary and acquired disorders, including severe combined immunodeficiency, 1 hemophilia, 2 and vascular diseases. 3 These advances were based on incremental improvements in vector systems, and these developments have been directly dependent on the availability and utility of appropriate model systems. Adenoviral-based approaches have shown some clinical utility for treatment of advanced malignant disease. [4] [5] [6] One of the most promising areas of cancer gene therapy is CRAds, the safety of which has been demonstrated for intratumoral, intraperitoneal, intra-arterial and intravenous administration. 42 Although single agent clinical efficacy has been relatively modest, [42] [43] [44] combination with chemotherapy has shown clinical efficacy. 4 To further develop the tumor-penetrating capabilities of CRAds, improved preclinical models are required for hypothesis testing in clinically relevant substrates.
While cell lines are widely used for analysis of antitumor agents, recent findings suggest that their levels of CAR may correspond poorly with those in primary tumor cells obtained from patient specimens. 11, 12, [16] [17] [18] [19] [20] [21] This discordance has crucial implications because the CAR level of any tumor may represent the key determinant of infectivity for Ad. 10, 11 In particular, advanced cases of various cancer types seem to express highly variable levels of CAR, 45, 46 and the expression may inversely correlate with the grade of the tumor. 45 CAR may be a part of the tight junction. 47 It could function as an adhesion molecule, 48 and its downregulation may be associated with overactivity of the RAS/MAPK pathway. 46 Importantly, it has been established that infectivity of target cells determines the oncolytic potential of a CRAd. [13] [14] [15] Therefore, primary tumor cells could provide a more stringent and clinically relevant model for analysis of replication competent viruses. The limited viability of unpassaged primary ovarian cancer cells in vitro, however, is insufficient to provide a useful substrate for CRAd assays. 27 Thus, we developed an approach based on forming spheroids of primary cancer cells purified from patient samples. The purification step may be crucial since contaminating nonneoplastic cells with genotypes and phenotypes different from tumor cells could confound infectivity data. Primary ovarian adenocarcinoma cells were cultured as spheroids for 1 and 30 days. Subsequent immunostaining with antibodies specific for adenocarcinoma, B72.3 and EMA, showed consistent reactivity (Fig 1b, c) . The persistent staining with these antibodies and the identical morphology after 30 days suggests that the spheroids of primary tumor cells were viable even after this prolonged culture. Furthermore, the consistent degree of staining and the histological appearance suggests that the proportion of tumor cells in the spheroids remains constant. Therefore, spheroids provide a novel means for retaining the viability of purified primary tumor cells.
A potential concern pertaining to the spheroid model is that the expression of surface receptors, which are required for viral infectivity and possibly cell adhesion, 48 in spheroids might be altered. Compared to monolayers, some spheroids systems have been shown to display variations in gene expression, 49, 50 morphology, 51, 52 and surface receptor expression. [53] [54] [55] [56] Such differences might impact the correlation of infectivity data from monolayers to spheroids, and more importantly, to in vivo tumors. To investigate this potential problem, we used an indirect means to assess the infectivity of spheroids and monolayers. Modification of the Ad fiber with an RGD-4C motif (Ad5lucRGD) enhances infectivity and improves transduction by allowing binding to both a v b group integrins and CAR, 22, 24, 41 whereas Ad with wild-type fiber, such as our isogenic control Ad5luc1, binds only to CAR and then undergoes subsequent integrin-mediated internalization. By comparing reporter gene expression mediated by Ad5lucRGD and Ad5luc1 in monolayers versus spheroids, we can thus indirectly estimate the relative expression levels of CAR and the relevant integrins. Importantly, the differences in reporter gene expression resulting from transduction with Ad5luc1 and Ad5lucRGD were very similar in monolayers in comparison to spheroids (Fig 2a-c) . This suggests that expression of the receptors relevant for Ad binding and entry does not markedly differ between monolayers and spheroids. Furthermore, the same was true for purified primary tumor cells (Fig 2d, e) .
Having established the validity of spheroids as a model for Ad infection, a replication competent Ad expressing luciferase (Ad5-Luc3) was used to assess replication and oncolysis in spheroids. Since luciferase is an intracellular protein, it is expected to be present in the supernatant only if its producer cells undergo lysis 37, 57 as they do during Ad replication. In addition, when luciferase is expressed from a nonreplicating vector, maximum production is observed between 24 and 72 hours. 58 Although supernatant was completely replaced daily for luciferase activity assay, it was detectable up to 14 days after infection (Fig 3a) . This persistence and increase of luciferase measurements up to day 6 (10 PFU/surface cell) provides preliminary evidence suggesting replication. As expected, infections with higher titers of virus reached peak supernatant luciferase levels earlier than those with lower titers. In addition, higher viral titers were associated with shorter durations of measurable supernatant luciferase levels.
When primary tumor cell spheroids were infected with Ad5-Luc3, luciferase was detected up to day 16 (Fig 3b) . Interestingly, the pattern of luciferase release differed from the cell line spheroids as maximum readings were detected only 1 day after infection. This variation could be because of the smaller average size but larger number of primary cell spheroids resulting in different kinetics of virus penetration and dispersion. It can be speculated that the transient decrease in luciferase activity on day 2 (100 and 1000 PFU/surface cell) might correspond with a second cycle of replication after a collective viral release on day 1 and before a second wave of viral dispersion on day 3. The quantitative differences seen in these experiments suggest that meaningful comparison of the replicative and oncolytic potential of different replicative viral vectors should be possible. Candidate clinical vectors can be evaluated by comparing their time to reach peak and baseline concentrations of the transgene product in the supernatant. More potent vectors might be expected to replicate and lyse tumor cells faster bringing shorter times to peak and baseline levels.
Ad5-D24RGD is a promising novel CRAd 34 currently undergoing preclinical evaluation for treatment of ovarian cancer patients. 59 Replication of this agent was tested on primary ovarian cancer cell spheroids (Fig 4) . At all viral doses, quantitative PCR detected an increase in viral DNA as a function of time, suggesting replication. The longer experiments allowed determination of viral DNA peak levels 8-15 days after infection and increases in viral DNA measuring two or three orders of magnitude (Fig  4b-d) . The first infection (Fig 4a) showed greater replication of Ad5-D24RGD ranging from five to nine orders of magnitude during a shorter course of only 5 days. This difference could possibly be because of the smaller size of spheroids from this patient sample, which might have led to greater initial infectivity and subsequently more rapid replication. To demonstrate more clearly the total replication achieved with each virus, cumulative amounts of virus were calculated (Fig 4e-h) . This read-out avoids confusion caused by daily variations in virus produced, and provides a clear visual end point. These methods can be applied to quantitation and comparison of other candidate clinical agents.
Interestingly, we observed replication of the E1-deleted control virus (Ad5LucRGD) on all samples tested. Wildtype contamination was not detected with PCR. Further, three ovarian cancer and one teratocarcinoma cell lines were infected with the same batch of this virus followed by incubation of up to 17 days, without evidence of cytopathic effect, suggesting lack of wild-type virus. 59 Possible reasons for this phenomenon include the presence of minute amounts of wild-type contaminant not detectable by PCR or on the cell lines. Alternatively, the primary cancer cells might have transcomplemented the missing E1 proteins. This phenomenon has been reported before with the presence of IL-6 or papillomavirus E6 and E7 allowing replication of E1-deleted viruses. [60] [61] [62] [63] [64] In fact, it was demonstrated that factors produced by primary ovarian cancer cells allowed similar replication of an E1-deleted virus and a wild-type adenovirus. 60 While xenografts have traditionally been utilized for investigation of therapeutic efficacy, receptor levels on these cancer cell lines may not correspond well with primary tumors. 11, 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In addition, in vitro assays are often more practical than in vivo analysis because they allow daily sampling and evaluation of the substrates. Furthermore, improved in vitro models could help reduce the need for animal testing. Importantly, primary tumor specimens represent the sole means for observing individual variability between clinical ovarian cancer cases. Thus, by providing a stringent model for assessing replicative agents on primary tumor substrates, spheroids should be useful for complementing therapeutic data from xenograft models. An interesting concept is a combined in vitro-in vivo model. Conceivably, in vitro spheroids could be inoculated subcutaneously or intraperitoneally in nude or SCID mice. This would provide an animal model based on purified primary tumor cells derived from a patient sample. In this paper, we used spheroids for analysis of CRAds, but the model should be applicable to any type of replicating agent. Replication competent viruses currently undergoing preclinical or clinical evaluation for cancer treatment include herpes simplex virus, 65, 66 vaccinia, 67 Newcastle disease virus, 68 parvovirus, 69 reovirus, 70 measles virus, 71 retrovirus, 72 influenza virus, 73 poliovirus, 74 vesicular stomatitis virus, 75 and avian sarcoma leucosis virus. 76 Therefore, replication competent viruses represent a dynamic field desperate for practical substrates for primary tumor specimen analyses.
In summary, we describe a novel approach for analyzing replication competent anticancer agents. Spheroids provide a three-dimensional model, which could represent in vivo tumors better than two-dimensional monolayers. Importantly, spheroids consisting of purified primary tumor cells would allow analysis of the most stringent available clinical substrates and eliminate possible confounding variables involved in working with cell lines. This model appears useful for analyzing replicative viral agents in primary tumor material, thereby providing crucial preclinical data for translational research.
